A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients [2]

Gut

Volumn 56, Issue 2, 2007, Pages 304-306

  Assy, N ^a   Adams, P C ^b   Myers, P ^b   Simon, V ^b   Ghent, C N ^b  

^a Rebecca Sieff Government Hospital   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; PLACEBO; PREDNISONE; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE REDUCTION; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER GRAFT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME;

CHOLAGOGUES AND CHOLERETICS; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; WITHHOLDING TREATMENT;

EID: 33847004049     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.107862     Document Type: Letter

References (9)

1. Pons JA, Yelamos J, Ramirez P, et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 2003;75:1045-7.
2. Ramos HC, Reyes J, Abo-Elmagd K, et al. Weaning of immunosuppression in long term liver transplant recipients. Transplantation 1995;59:212-17.
3. Sandborn WJ, Hay JE, Porayko MK, et al. Cyclosporin withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994;19:925-32.
4. Presson H, Friman S, Schersten T, et al. Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. Lancet 1990;336:52-3.
5. Lazaridis KN, Cores GJ, Lindor KD. Ursodeoxvcholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol 2001;35:134-46.
6. Yoshikawa MY, Tsujii T, Matsunura Y, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992;16:358-64.
7. Calmus Y, Guechot J, Podevin P, et al. Differential effects of chenodeoxycholic acid and ursodeoxycholic acids on interleukin 1, interleukin and tumor necrosis factor alpha production by monocytes. Hepatology 1992;16:719-23.
8. Gonzalez A, Czaja A, Carpenter H, et al. Recurrent autoimmune hepatitis after othotopic liver transplantation. Liver Transpl 2001;7:302-10.
9. Pageaux GP, Bismuth M, Perney P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol 2003;38:629-34.